Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).
The main questions it aims to answer are:
* Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results?
* Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC
* Receive Cadonilimab combined with SRT for brain lesions.
* Visit the hospital regularly once every 12 weeks for checkups and tests